Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Shareholder Meeting (October 2021)
10 slides from Oncosil Medical's shareholder meeting presentation, Oct 19, 2021
Slide 1: CEO AGM Presentation
CEO AGM Presentation 19 October 2021
Slide 2: OncoSil's targeted approach to pancreatic cancer treatment
OncoSil Medical’s targeted approach will deliver a positive impact in the treatment of pancreatic cancer, aimed at extending the length and quality of life for patients 2 • CEO AGM Presentation • 19 October 2021
Slide 3: OncoSil Device Overview
OncoSil™ Device Overview OncoSil™ is intended OncoSil™ is for the treatment of implanted directly locally advanced into a pancreatic tumour unresectable via injection under pancreatic cancer, endoscopic in combination with 98% ultrasound of all gemcitabine-based guidance. radiation is chemotherapy.
Slide 4: Management Team with a Depth of Experience and Expertise
Management Team with a Depth of Experience and Expertise Nigel Dr Ralph David Henk Lange Peters Turner Tissing Managing Chief Medical Head of Director of Clinical Director & CEO Officer Medical Affairs Development 30+ years 30+ years 25+ years experience in experience in diagnostic and 40+ years ind
Slide 5: Achievements so far
Achievements so far Current Market Approvals Europe (CE Mark) PanCO Study completed United Kingdom Switzerland Singapore Malaysia CE Marking obtained Hong Kong New Zealand Turkey Israel Breakthrough device designation achieved in US, EU, UK, Singapore Enabled HDE pathway for bile duct cancer in US e
Slide 6: Go-To Market Execution Progress
Go-To Market Execution Progress Ethics applications in progress in over Preparation of 25 hospitals in the following markets: Training to be completed by UK, Germany, France, Spain, Italy, end of November 2021 OSPREY Sites Portugal, Turkey and Israel. Initiated first steps in developing a Preparatio
Slide 7: HDE Application for Distal Cholangiocarcinoma
HDE Application for Distal Cholangiocarcinoma Where are we now? On 28 July 2020, Humanitarian Device Exemption (HDE) application submitted with Updated data set resubmitted with the US FDA for its OncoSil™ device in the the FDA – hundreds of documents treatment of distal cholangiocarcinoma.* and tho
Slide 8: Commercial Opportunity Expansion
Commercial Opportunity Expansion Current Position: Expansion opportunity: • Approved in: • Commercialise OncoSil™ device in the USA under FDA HDE approval - Europe (CE Mark) - New Zealand • Expand Label to include FOLFIRINOX chemo - Switzerland - United Kingdom • Alternative device delivery methods
Slide 9: Disclaimer
Disclaimer This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the informat
Slide 10: Nigel Lange
Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com OncoSil Medical Ltd www.oncosil.com T: +49 160 9642 4981